Cargando…
Mechanistic Analysis of Age-Related Clinical Manifestations in Down Syndrome
Down syndrome (DS) is the most common genetic cause of Alzheimer’s disease (AD) due to trisomy for all or part of human chromosome 21 (Hsa21). It is also associated with other phenotypes including distinctive facial features, cardiac defects, growth delay, intellectual disability, immune system abno...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8281234/ https://www.ncbi.nlm.nih.gov/pubmed/34276349 http://dx.doi.org/10.3389/fnagi.2021.700280 |
_version_ | 1783722807110139904 |
---|---|
author | Chen, Xu-Qiao Xing, Zhuo Chen, Quang-Di Salvi, Richard J. Zhang, Xuming Tycko, Benjamin Mobley, William C. Yu, Y. Eugene |
author_facet | Chen, Xu-Qiao Xing, Zhuo Chen, Quang-Di Salvi, Richard J. Zhang, Xuming Tycko, Benjamin Mobley, William C. Yu, Y. Eugene |
author_sort | Chen, Xu-Qiao |
collection | PubMed |
description | Down syndrome (DS) is the most common genetic cause of Alzheimer’s disease (AD) due to trisomy for all or part of human chromosome 21 (Hsa21). It is also associated with other phenotypes including distinctive facial features, cardiac defects, growth delay, intellectual disability, immune system abnormalities, and hearing loss. All adults with DS demonstrate AD-like brain pathology, including amyloid plaques and neurofibrillary tangles, by age 40 and dementia typically by age 60. There is compelling evidence that increased APP gene dose is necessary for AD in DS, and the mechanism for this effect has begun to emerge, implicating the C-terminal APP fragment of 99 amino acid (β-CTF). The products of other triplicated genes on Hsa21 might act to modify the impact of APP triplication by altering the overall rate of biological aging. Another important age-related DS phenotype is hearing loss, and while its mechanism is unknown, we describe its characteristics here. Moreover, immune system abnormalities in DS, involving interferon pathway genes and aging, predispose to diverse infections and might modify the severity of COVID-19. All these considerations suggest human trisomy 21 impacts several diseases in an age-dependent manner. Thus, understanding the possible aging-related mechanisms associated with these clinical manifestations of DS will facilitate therapeutic interventions in mid-to-late adulthood, while at the same time shedding light on basic mechanisms of aging. |
format | Online Article Text |
id | pubmed-8281234 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82812342021-07-16 Mechanistic Analysis of Age-Related Clinical Manifestations in Down Syndrome Chen, Xu-Qiao Xing, Zhuo Chen, Quang-Di Salvi, Richard J. Zhang, Xuming Tycko, Benjamin Mobley, William C. Yu, Y. Eugene Front Aging Neurosci Neuroscience Down syndrome (DS) is the most common genetic cause of Alzheimer’s disease (AD) due to trisomy for all or part of human chromosome 21 (Hsa21). It is also associated with other phenotypes including distinctive facial features, cardiac defects, growth delay, intellectual disability, immune system abnormalities, and hearing loss. All adults with DS demonstrate AD-like brain pathology, including amyloid plaques and neurofibrillary tangles, by age 40 and dementia typically by age 60. There is compelling evidence that increased APP gene dose is necessary for AD in DS, and the mechanism for this effect has begun to emerge, implicating the C-terminal APP fragment of 99 amino acid (β-CTF). The products of other triplicated genes on Hsa21 might act to modify the impact of APP triplication by altering the overall rate of biological aging. Another important age-related DS phenotype is hearing loss, and while its mechanism is unknown, we describe its characteristics here. Moreover, immune system abnormalities in DS, involving interferon pathway genes and aging, predispose to diverse infections and might modify the severity of COVID-19. All these considerations suggest human trisomy 21 impacts several diseases in an age-dependent manner. Thus, understanding the possible aging-related mechanisms associated with these clinical manifestations of DS will facilitate therapeutic interventions in mid-to-late adulthood, while at the same time shedding light on basic mechanisms of aging. Frontiers Media S.A. 2021-07-01 /pmc/articles/PMC8281234/ /pubmed/34276349 http://dx.doi.org/10.3389/fnagi.2021.700280 Text en Copyright © 2021 Chen, Xing, Chen, Salvi, Zhang, Tycko, Mobley and Yu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Chen, Xu-Qiao Xing, Zhuo Chen, Quang-Di Salvi, Richard J. Zhang, Xuming Tycko, Benjamin Mobley, William C. Yu, Y. Eugene Mechanistic Analysis of Age-Related Clinical Manifestations in Down Syndrome |
title | Mechanistic Analysis of Age-Related Clinical Manifestations in Down Syndrome |
title_full | Mechanistic Analysis of Age-Related Clinical Manifestations in Down Syndrome |
title_fullStr | Mechanistic Analysis of Age-Related Clinical Manifestations in Down Syndrome |
title_full_unstemmed | Mechanistic Analysis of Age-Related Clinical Manifestations in Down Syndrome |
title_short | Mechanistic Analysis of Age-Related Clinical Manifestations in Down Syndrome |
title_sort | mechanistic analysis of age-related clinical manifestations in down syndrome |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8281234/ https://www.ncbi.nlm.nih.gov/pubmed/34276349 http://dx.doi.org/10.3389/fnagi.2021.700280 |
work_keys_str_mv | AT chenxuqiao mechanisticanalysisofagerelatedclinicalmanifestationsindownsyndrome AT xingzhuo mechanisticanalysisofagerelatedclinicalmanifestationsindownsyndrome AT chenquangdi mechanisticanalysisofagerelatedclinicalmanifestationsindownsyndrome AT salvirichardj mechanisticanalysisofagerelatedclinicalmanifestationsindownsyndrome AT zhangxuming mechanisticanalysisofagerelatedclinicalmanifestationsindownsyndrome AT tyckobenjamin mechanisticanalysisofagerelatedclinicalmanifestationsindownsyndrome AT mobleywilliamc mechanisticanalysisofagerelatedclinicalmanifestationsindownsyndrome AT yuyeugene mechanisticanalysisofagerelatedclinicalmanifestationsindownsyndrome |